First test of dual vaccine targets two common respiratory viruses
NCT ID NCT06556147
Summary
This is an early-stage study to test the safety and immune response of a new vaccine candidate, VXB-241. The goal is to see if it can help prevent serious lung infections caused by two common viruses: Respiratory Syncytial Virus (RSV) and human metapneumovirus (HMPV). The study will enroll 144 healthy adults, primarily focusing on people aged 60 to 83, to test four different dose levels and see how a second shot given a year later affects the immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of the Sunshine Coast
Morayfield, Queensland, 4506, Australia
-
University of the Sunshine Coast
Sippy Downs, Queensland, 4556, Australia
-
University of the Sunshine Coast
South Brisbane, Queensland, 4101, Australia
-
Veritus Research
Bayswater, Victoria, 3153, Australia
Conditions
Explore the condition pages connected to this study.